ESTRO 2024 - Abstract Book

S1521

Clinical - Lower GI

ESTRO 2024

Material/Methods:

The clinical audits consist of the evaluation of clinical, diagnostic, and treatment-related data (including all relevant medical, dosimetric, and technical data) for 100 patients per tumour site (rectal and prostate cancer) to verify adherence to a predetermined set of quality indicators. The audits were performed by analysing medical records of patients who underwent radiotherapy as part of their treatment plan between January 1, 2018 and December 31, 2019. After patient selection, the data of interest (as established in the study protocol) were entered into a central database for subsequent analysis. The following six comprehensive European centres participated in the multicentre, international clinical audit as part of the IROCA project: Catalan Institute of Oncology (ICO, Barcelona, Spain); Greater Poland Cancer Centre (GPCC; Poznan, Poland); Instituto Português de Oncologia do Porto Francisco Gentil (IPO, Porto, Portugal); University Hospital Maggiore della Carità (AOU Novara, Italy); Cancer Institute of Montpellier (ICM, Montpellier, France) and The Oncology Institute Prof. Dr. Ion Chiricuta (IOCN, Cluj Napoca, Romania). For the analysis, the three hospitals in Catalonia, Spain (ICO Hospitalet, ICO Badalona, and ICO Girona) will be considered as a single centre.

Results:

Figure 1. Patient accrual by centre and cancer type.

Patient accrual results are presented in Fig. 1. The following results concerning diagnosis and treatment were obtained: Pre-treatment pelvic MRI was performed in 90.7% of rectal and 83.5% of prostate cancer cases (last audit: 87.3% of all patients), diagnostic thoracoabdominal computed tomography (CT) in 87.1% for rectal cancer patients (last audit: 81.9% of cases). For rectal cancer patients, 76.2% (last audit: 63.8%) and 94.6% (last audit: 75.6%) were presented to the DCS and MTB, respectively. Patients were diagnosed at a different hospital (regional hospital or other) in 87.9% of rectal cancer cases and 84.3% of prostate cancer cases. 7.7% of rectal cancer and 15.2% of prostate cancer patients have been included in a clinical trial. Rectal cancer patients were treated with the following radiotherapy techniques: 3DCRT (34.1%), VMAT (37.1%), IMRT (28.8%), whereas prostate cancer patients were treated with: 3DCRT (0.6%), IMRT (7.4%), VMAT (78.9%), CyberKnife (12.3%), SBRT (0.9%). Treatment interruptions ≥ one day were observed in 41.1% - rectal and 43,9% - prostate cases (last audit: 43.9%).

Conclusion:

While many departments and hospitals routinely perform clinical audits, multicentre audits are relatively rare, especially in the field of radiation oncology. In this regard, multicentre, international audits are highly valuable as